Financial News
Biohaven eyes mid-2021 for migraine prevention drug launch
November 18, 2020 at 20:14 PM EST
"I hope that in 6 months or so from now that we will be the first oral CGRP with the indication for the prevention of migraine," Biohaven CEO Vlad Coric said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
